A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults

Trial Profile

A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Shigella sonnei vaccine (Primary) ; Shigella sonnei vaccine (Primary) ; Shigella sonnei vaccine (Primary)
  • Indications Shigella infections
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 05 Jan 2016 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 11 Dec 2014 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 11 Dec 2014 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top